Videos

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.

Pharmacy Times® interviewed Alan Green, the US head of sales, infectious disease at AstraZeneca, on the Flu+Force campaign and the resources it provides to help pharmacists develop alternative flu vaccination sites.

Randall A. Oyer, MD, discusses rising cancer mortality during the coronavirus disease 2019 (COVID-19) pandemic and what that means for cancer care.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the disease impact on the gynecologic system and how often patients become infertile due to this impact.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, details the treatment options available for patients with congenital plasminogen deficiency.

Pharmacy Times spoke with Jeremy Barnett, LMHC, CASAC & Expert at Help.org, about recommended plans and advice for those who are struggling with addiction during the holidays and the COVID-19 pandemic.

Pharmacy Times spoke with Jeremy Barnett, LMHC, CASAC & Expert at Help.org, about substance abuse dangers during COVID-19 and the holiday season.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, describes common manifestations of congenital plasminogen deficiency and their impact on patient outcomes.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.

Pharmacy Times® interviewed Michael Flannery, PharmD, the assistant director of pharmacy operations at the University of Rochester Medical Center, on the process for managing the waiting period in the pharmacy following COVID-19 immunizations.

Pharmacy Times® interviewed Michael Flannery, PharmD, the assistant director of pharmacy operations at the University of Rochester Medical Center, on the process for immunizing staff at a hospital pharmacy with the COVID-19 vaccines.

Pharmacy Times® interviewed Michael Flannery, PharmD, of the University of Rochester Medical Center, on the process that the hospital pharmacy has developed for vaccinations following the arrival of the Pfizer and Moderna COVID-19 vaccines.

Pharmacy Times® interviewed Jason Kay, PharmD, MS, the director of pharmacy programs at of Blue Cross Blue Shield Association, on how the recent drop in immunizations among children may result in the rise of certain highly contagious diseases.

Pharmacy Times® interviewed Michael Flannery, PharmD, the assistant director of pharmacy operations at the University of Rochester Medical Center, on the concerns he has regarding the COVID-19 vaccination process ahead.

Pharmacy Times® interviewed Emily Cook, JD, a partner with McDermott Will & Emery, on the final 340B dispute resolution rule, which was recently sent by the HHS to the OMB for review.

Pharmacy Times® interviewed Sue Peschin of the COVID-19 Vaccine Education and Equity Project on the role of pharmacies in vaccinating the public with the COVID-19 vaccines.

Pharmacy Times® interviewed Sue Peschin, president and CEO of Alliance for Aging Research, on the work that the COVID-19 Vaccine Education and Equity Project is doing to engage diverse constituencies on the importance of the clinical trials process, regulatory review, and equitable access to COVID-19 vaccines.

Pharmacy Times® interviewed Sue Peschin, president and CEO of Alliance for Aging Research, on the work that the COVID-19 Vaccine Education and Equity Project is doing to support education about and equitable access to COVID-19 vaccines.

Pharmacists, physicians, and nurses have been among the first to receive COVID-19 vaccinations at health care facilities across the country.

Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on how pharmacists can help people come back for the second dose of the COVID-19 vaccine.

Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on some of the challenges community pharmacies may need to manage when receiving and administering COVID-19 vaccines.

Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on the work needed to prepare for the arrival and administration of COVID-19 vaccines.

Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Pharmacy Times® interviewed Signe Pringle, the assistant secretary for the Maryland Department of Commerce, on a signed partnership between Quebec and Maryland to foster collaboration around health science research during COVID-19 and beyond.

Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray describes what she hopes to see for future trials involving sickle cell disease and rivipansel for acute vaso-occlusive crisis.

In an interview with Pharmacy Times, Helen Thackray, MD, Thackray emphasizes the importance of administering rivipansel early in vaso-occlusive crisis and how it is meaningful for both adults and children with sickle cell disease.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.